Emerging pharmacotherapy for cancer patients with cognitive dysfunction

Download
Author
Davis, J; Ahlberg, FM; Berk, M; Ashley, DM; Khasraw, MDate
2013-10-24Source Title
BMC NeurologyPublisher
BIOMED CENTRAL LTDUniversity of Melbourne Author/s
Berk, MichaelAffiliation
PsychiatryMetadata
Show full item recordDocument Type
Journal ArticleCitations
Davis, J., Ahlberg, F. M., Berk, M., Ashley, D. M. & Khasraw, M. (2013). Emerging pharmacotherapy for cancer patients with cognitive dysfunction. BMC NEUROLOGY, 13 (1), https://doi.org/10.1186/1471-2377-13-153.Access Status
Open AccessAbstract
Advances in the diagnosis and multi-modality treatment of cancer have increased survival rates for many cancer types leading to an increasing load of long-term sequelae of therapy, including that of cognitive dysfunction. The cytotoxic nature of chemotherapeutic agents may also reduce neurogenesis, a key component of the physiology of memory and cognition, with ramifications for the patient's mood and other cognition disorders. Similarly radiotherapy employed as a therapeutic or prophylactic tool in the treatment of primary or metastatic disease may significantly affect cognition. A number of emerging pharmacotherapies are under investigation for the treatment of cognitive dysfunction experienced by cancer patients. Recent data from clinical trials is reviewed involving the stimulants modafinil and methylphenidate, mood stabiliser lithium, anti-Alzheimer's drugs memantine and donepezil, as well as other agents which are currently being explored within dementia, animal, and cell culture models to evaluate their use in treating cognitive dysfunction.
Export Reference in RIS Format
Endnote
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
Refworks
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References
Collections
- Minerva Elements Records [53039]
- Psychiatry - Research Publications [1379]